Abstract
Since 2000, several studies have reported positive results in reasonable-size randomized controlled trials of adjuvant treatment for potentially curable gastric cancer. At present, postoperative adjuvant chemoradiotherapy and perioperative chemotherapy are the standard of care in the United States and Europe (including Great Britain), respectively, while postoperative S-1 monotherapy is the standard of care in Japan. The effect of adjuvant treatment varies according to the type of surgery, and the best results so far have been observed in the adjuvant chemotherapy of TS-1 for gastric cancer (ACTS-GC) trial, in which D2 surgery followed by S-1 monotherapy was tested. The role of radiotherapy after D2 dissection remains unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
